Competing Risk Analysis for Diabetes Mellitus Mortality in Bladder Cancer Patients: A Population-based Study.

IF 2.3 4区 医学 Q3 ONCOLOGY
Shunde Wang, Baishu Zheng, Junjie Yang, Junyong Zhang
{"title":"Competing Risk Analysis for Diabetes Mellitus Mortality in Bladder Cancer Patients: A Population-based Study.","authors":"Shunde Wang, Baishu Zheng, Junjie Yang, Junyong Zhang","doi":"10.2174/0115680096356675250217074915","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Historically, there has been a lack of focus on the mortality rates of individuals with both diabetes and Bladder Bancer (BC). Our study aimed to identify the risk factors associated with death from Diabetes Mellitus (DM) in BC patients.</p><p><strong>Methods: </strong>Data was gathered from the SEER database on individuals who were diagnosed with BC between the years 2000 and 2017. Calculation of the Standardized Mortality Ratio (SMR) was performed to determine the mortality rate of DM in patients from BC. Potential risk factors for DM mortality were identified by a multivariate competing risk model. Haz-ard Ratios (HR), with 95% confidence intervals (95% CI) were used to indicate the degree of associated risk.</p><p><strong>Results: </strong>A total of 217,230 BC patients' data were collected from the SEER database for analysis. Among them, 98,880 patients passed away, and 1,783 patients encountered DM mortality. The overall SMR for DM mortality in BC patients was 3.32 (95% CI: 3.17-3.48). Results indicated that SMR increased with increasing years but decreased with increasing follow-up time. Multivariate competing risk analysis shows that BC patients with the fol-lowing factors were at higher risk of developing DM mortality: advanced age, male, black, in situ tumor stage, early year of diagnosis, pathology type of transitional cell carcinoma, without chemotherapy or radiation therapy, and absence of spouse (including separated, di-vorced, widowed, and unmarried).</p><p><strong>Conclusion: </strong>Individuals diagnosed with BC are at a considerably elevated risk of mortality from DM compared to the general population. It is of the utmost importance to identify high-risk groups and implement effective interventions for DM in order to enhance the sur-vival rate among this patient population.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096356675250217074915","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Historically, there has been a lack of focus on the mortality rates of individuals with both diabetes and Bladder Bancer (BC). Our study aimed to identify the risk factors associated with death from Diabetes Mellitus (DM) in BC patients.

Methods: Data was gathered from the SEER database on individuals who were diagnosed with BC between the years 2000 and 2017. Calculation of the Standardized Mortality Ratio (SMR) was performed to determine the mortality rate of DM in patients from BC. Potential risk factors for DM mortality were identified by a multivariate competing risk model. Haz-ard Ratios (HR), with 95% confidence intervals (95% CI) were used to indicate the degree of associated risk.

Results: A total of 217,230 BC patients' data were collected from the SEER database for analysis. Among them, 98,880 patients passed away, and 1,783 patients encountered DM mortality. The overall SMR for DM mortality in BC patients was 3.32 (95% CI: 3.17-3.48). Results indicated that SMR increased with increasing years but decreased with increasing follow-up time. Multivariate competing risk analysis shows that BC patients with the fol-lowing factors were at higher risk of developing DM mortality: advanced age, male, black, in situ tumor stage, early year of diagnosis, pathology type of transitional cell carcinoma, without chemotherapy or radiation therapy, and absence of spouse (including separated, di-vorced, widowed, and unmarried).

Conclusion: Individuals diagnosed with BC are at a considerably elevated risk of mortality from DM compared to the general population. It is of the utmost importance to identify high-risk groups and implement effective interventions for DM in order to enhance the sur-vival rate among this patient population.

膀胱癌患者糖尿病死亡率的竞争风险分析:一项基于人群的研究
背景:历史上,一直缺乏对糖尿病和膀胱平衡癌(BC)患者死亡率的关注。我们的研究旨在确定与BC患者糖尿病(DM)死亡相关的危险因素。方法:从SEER数据库中收集2000年至2017年间诊断为BC的个体的数据。计算标准化死亡率(SMR)以确定BC患者糖尿病的死亡率。通过多变量竞争风险模型确定糖尿病死亡率的潜在危险因素。使用风险比(HR)和95%置信区间(95% CI)来表示相关风险的程度。结果:从SEER数据库中共收集了217,230例BC患者的数据进行分析。其中死亡98880例,糖尿病死亡1783例。BC患者糖尿病死亡率的总SMR为3.32 (95% CI: 3.17-3.48)。结果表明,SMR随随访时间的增加而增加,随随访时间的增加而降低。多因素竞争风险分析显示:高龄、男性、黑人、原位肿瘤分期、早期诊断、移行细胞癌病理类型、未接受化疗或放疗、无配偶(包括分居、离异、丧偶和未婚)的BC患者发生糖尿病死亡的风险较高。结论:与一般人群相比,被诊断为BC的个体因糖尿病死亡的风险相当高。识别糖尿病的高危人群并实施有效的干预措施对于提高糖尿病患者的生存率至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current cancer drug targets
Current cancer drug targets 医学-肿瘤学
CiteScore
5.40
自引率
0.00%
发文量
105
审稿时长
1 months
期刊介绍: Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信